Consensus Thermo Fisher Scientific, Inc.
Equities
TMO
US8835561023
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 572.77 USD | -0.43% |
|
-3.06% | +10.10% |
| Dec. 04 | GENinCode inks commercialisation deal with Thermo Fisher | AN |
| Dec. 04 | GENinCode Partners with US-based Thermo Fisher to Commercialize Heart Disease Test | MT |
Evolution of the Average Target: Thermo Fisher Scientific, Inc.
Evolution of the Target Price: Thermo Fisher Scientific, Inc.
Changes in Analyst Recommendations: Thermo Fisher Scientific, Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +8.24% | |||||
| +3.65% | |||||
| +13% | |||||
| +29.7% | |||||
| +31.22% | |||||
| +10.49% | |||||
| +16.43% | |||||
| +3.1% | |||||
| +14.39% | |||||
| +38.37% | |||||
| Average | +16.86% | |||||
| Weighted average by Cap. | +14.09% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Morgan Stanley | |
| HSBC | |
| Argus | |
| UBS | |
| Deutsche Bank Securities | |
| Raymond James | |
| Baird | |
| Wolfe Research | |
| Wells Fargo Securities | |
| Leerink Partners | |
| Jefferies & Co. | |
| Citigroup | |
| TD Cowen | |
| Barclays | |
| JPMorgan Chase | |
| Evercore ISI | |
| BofA Securities | |
| Rothschild & Co Redburn | |
| RBC Capital Markets | |
| William Blair & Co. | |
| Bernstein | |
| Stifel Nicolaus | |
| Scotiabank | |
| Redburn Atlantic | |
| Stephens Inc. | |
| Goldman Sachs | |
| Nephron Research | |
| CMB International | |
| ARC Independent Research | |
| China Merchants | |
| KeyBanc Capital Markets | |
| Atlantic Equities | |
| Morningstar | |
| Credit Suisse | |
| Cowen | |
| SVB Securities LLC | |
| SVB Leerink | |
| BTIG | |
| Benchmark Capital | |
| J.P. Morgan Chase |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TMO Stock
- Consensus Thermo Fisher Scientific, Inc.
Select your edition
All financial news and data tailored to specific country editions
